BR112019001572A2 - nova formulação administrável por via oral - Google Patents

nova formulação administrável por via oral

Info

Publication number
BR112019001572A2
BR112019001572A2 BR112019001572-8A BR112019001572A BR112019001572A2 BR 112019001572 A2 BR112019001572 A2 BR 112019001572A2 BR 112019001572 A BR112019001572 A BR 112019001572A BR 112019001572 A2 BR112019001572 A2 BR 112019001572A2
Authority
BR
Brazil
Prior art keywords
orally administrable
formulation
administrable formulation
pharmaceutical agent
new orally
Prior art date
Application number
BR112019001572-8A
Other languages
English (en)
Other versions
BR112019001572B1 (pt
Inventor
Greenspoon Allen
Original Assignee
Greenspoon Allen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenspoon Allen filed Critical Greenspoon Allen
Priority to BR122020007418-3A priority Critical patent/BR122020007418B1/pt
Publication of BR112019001572A2 publication Critical patent/BR112019001572A2/pt
Publication of BR112019001572B1 publication Critical patent/BR112019001572B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uma formulação de goma de mascar administrável por via oral é fornecida compreendendo uma base de goma farmaceuticamente aceitável e partículas de um agente farmacêutico que variam em tamanho de cerca de 50 a cerca de 2000 µm, em que a formulação compreende cerca de 0,5-30% em peso das partículas do agente farmacêutico. uma formulação líquida compreendendo partículas de um agente farmacêutico é também fornecida.
BR112019001572-8A 2016-07-28 2017-07-28 Formulação de goma de mascar administrável por via oral BR112019001572B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020007418-3A BR122020007418B1 (pt) 2016-07-28 2017-07-28 Suspensão líquida oral à base de água

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/222,019 US9833408B1 (en) 2016-07-28 2016-07-28 Orally administrable formulation
US15/222,019 2016-07-28
PCT/CA2017/050904 WO2018018152A1 (en) 2016-07-28 2017-07-28 Novel orally administrable formulation

Publications (2)

Publication Number Publication Date
BR112019001572A2 true BR112019001572A2 (pt) 2019-05-07
BR112019001572B1 BR112019001572B1 (pt) 2021-11-03

Family

ID=60451833

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020007418-3A BR122020007418B1 (pt) 2016-07-28 2017-07-28 Suspensão líquida oral à base de água
BR112019001572-8A BR112019001572B1 (pt) 2016-07-28 2017-07-28 Formulação de goma de mascar administrável por via oral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020007418-3A BR122020007418B1 (pt) 2016-07-28 2017-07-28 Suspensão líquida oral à base de água

Country Status (13)

Country Link
US (2) US9833408B1 (pt)
EP (2) EP3490539B1 (pt)
JP (2) JP7050777B2 (pt)
AU (2) AU2017301239B2 (pt)
BR (2) BR122020007418B1 (pt)
CL (1) CL2019000209A1 (pt)
CO (1) CO2019001895A2 (pt)
CU (1) CU20190005A7 (pt)
IL (1) IL264484A (pt)
MX (1) MX2019001169A (pt)
PE (1) PE20190738A1 (pt)
WO (1) WO2018018152A1 (pt)
ZA (2) ZA201901116B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US11397962B2 (en) 2017-10-09 2022-07-26 American Express Travel Related Services Company, Inc. Loyalty point distributions using a decentralized loyalty ID
US11449887B2 (en) 2017-10-09 2022-09-20 American Express Travel Related Services Company, Inc. Systems and methods for loyalty point distribution
US11699166B2 (en) 2017-10-09 2023-07-11 American Express Travel Related Services Company, Inc. Multi-merchant loyalty point partnership
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3549579A1 (en) * 2018-04-03 2019-10-09 Sanofi Winthrop Industrie Oral gum formulation and fabrication process thereof
MX2020010424A (es) * 2018-04-03 2021-01-15 Pure Green Pharmaceuticals Inc Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
US11728995B2 (en) 2018-04-09 2023-08-15 American Express Travel Related Services Company, Inc. Reward point transfers using blockchain
US10783545B2 (en) 2018-04-19 2020-09-22 American Express Travel Related Services Company, Inc. Reward point redemption for cryptocurrency
WO2020061584A1 (en) * 2018-09-21 2020-03-26 Msb Holdings, Inc. Taste-masked dosage forms
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
MX2021008935A (es) * 2019-01-25 2021-08-24 Nordiccan As Goma de mascar de cannabinoide con alcoholes de azucar.
WO2020151790A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Cannabinoid chewing gum with high intensity sweeteners
US11191720B2 (en) 2019-01-25 2021-12-07 Nordiccan A/S Chewing gum with improved delivery of cannabinoids
WO2020151793A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Chewing gum with improved delivery of cannabinoids
US11154496B2 (en) * 2019-01-25 2021-10-26 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11013685B2 (en) * 2019-01-25 2021-05-25 Nordiccan A/S Cannabinoid chewing gum with improved release of cannabinoids
WO2020151792A1 (en) * 2019-01-25 2020-07-30 Medcan Pharma A/S Cannabinoid chewing gum with improved release of cannabinoids
AU2019425173B2 (en) * 2019-01-25 2023-01-05 Nordiccan A/S Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
US11406593B2 (en) 2019-01-25 2022-08-09 Nordiccan A/S Cannabinoid chewing gum with high intensity sweeteners
US10933017B2 (en) 2019-03-01 2021-03-02 Nordiccan A/S Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers
US11253473B2 (en) * 2019-03-01 2022-02-22 Nordiccan A/S Method of producing tableted cannabinoid chewing gum
US10799450B2 (en) 2019-03-01 2020-10-13 Medcan Pharma A/S Tableted cannabinoid chewing gum with layered structure
US11471405B2 (en) 2019-03-01 2022-10-18 Nordiccan A/S Tableted chewing gum with enhanced delivery of cannabinoids
US11331309B2 (en) 2019-06-05 2022-05-17 Cure Pharmaceutical Holding Corp. Methods and compositions for improving sleep
WO2021026557A1 (en) * 2019-08-02 2021-02-11 Advanced Female Technologies Llc Chewing gum compositions containing cannabinoids
WO2021084543A1 (en) * 2019-10-31 2021-05-06 M. Mustix Ltd Treatment of tooth decay using a chewing gum composition comprising cannabinoids
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
WO2021116825A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
US11363834B2 (en) 2020-10-01 2022-06-21 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing, product, and method of making the same
US11058142B1 (en) 2020-10-01 2021-07-13 Tobacco Technology, Inc. Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same
EP4243797A4 (en) * 2020-11-16 2024-11-13 Orcosa Inc RAPID INFUSION PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
CA3234805A1 (en) * 2021-10-11 2023-04-20 C. Russell Thomas Biphasic compositions comprising one or both of carbonate and phosphate

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816265A (en) * 1986-12-23 1989-03-28 Warner-Lambert Company Sweetener delivery systems containing polyvinyl acetate
DK505588D0 (da) * 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
US6132762A (en) * 1997-05-05 2000-10-17 Cristobal; Walter Transcutaneous application of marijuana
US7648696B2 (en) * 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
JP5599961B2 (ja) * 2000-03-09 2014-10-01 ジーダブリュー・ファーマ・リミテッド 薬学的組成物
EP1341523B1 (en) * 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
EP2286793A3 (en) * 2001-02-14 2014-01-08 GW Pharma Limited Pharmaceutical formulations comprising cannabidiol
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
BRPI0715328A2 (pt) * 2006-08-04 2013-07-09 Insys Therapeutics Inc formulaÇço, e, dispositivo de dose unitÁria ou de dose méltipla para a administraÇço sublingual de uma droga
EP2184983A1 (en) * 2007-08-06 2010-05-19 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
BRPI0910094B1 (pt) * 2008-03-26 2021-08-10 Stichting Sanammad Composição de goma de mascar, e, blíster
KR20110053983A (ko) * 2008-08-29 2011-05-24 썬 파마 어드밴스트 리서치 컴패니 리미티드 미립자
JP5614571B2 (ja) 2009-12-25 2014-10-29 ダイヤ製薬株式会社 咀嚼用ガム医薬品および咀嚼用ガム医薬品の製造方法
US10111831B2 (en) 2011-02-28 2018-10-30 Technologies Khloros Inc. Chewable vehicle for mouth absorption
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
WO2014159688A1 (en) * 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US10071053B2 (en) * 2014-01-31 2018-09-11 Pocket Tea, Llc Tea composition for oral administration
US20160199299A1 (en) 2015-01-09 2016-07-14 Mark B. Uren Cannabis Infused Chewing Composition
CN105124747B (zh) 2015-07-21 2018-04-10 中国烟草总公司广东省公司 一种烟草提取物微粒和胶基型口香烟及其制备方法
WO2017202424A1 (en) 2016-05-27 2017-11-30 Medcan Pharma A/S Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
CA3028160C (en) * 2016-07-28 2021-03-30 Allen Greenspoon Orally administrable formulation

Also Published As

Publication number Publication date
JP2019525963A (ja) 2019-09-12
ZA202001037B (en) 2020-07-29
CU20190005A7 (es) 2020-03-04
WO2018018152A1 (en) 2018-02-01
BR112019001572B1 (pt) 2021-11-03
EP3490539A4 (en) 2020-08-12
EP4353221A3 (en) 2024-07-10
AU2020257071B2 (en) 2021-03-25
US20180064645A1 (en) 2018-03-08
US9833408B1 (en) 2017-12-05
US10456357B2 (en) 2019-10-29
EP4353221A2 (en) 2024-04-17
IL264484A (en) 2019-02-28
JP2022088537A (ja) 2022-06-14
JP7050777B2 (ja) 2022-04-08
AU2017301239B2 (en) 2020-10-08
CL2019000209A1 (es) 2019-09-27
AU2020257071A1 (en) 2020-11-19
CO2019001895A2 (es) 2019-05-31
MX2019001169A (es) 2019-08-29
ZA201901116B (en) 2020-10-28
AU2017301239A1 (en) 2019-03-14
EP3490539A1 (en) 2019-06-05
PE20190738A1 (es) 2019-05-23
BR122020007418B1 (pt) 2021-11-03
EP3490539B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
BR112019001572A2 (pt) nova formulação administrável por via oral
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
BRPI1007945B8 (pt) formulação farmacêutica de liberação controlada de nitazoxamida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
BRPI0919753B8 (pt) forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
EA202090984A1 (ru) Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
BR112014014127A2 (pt) composições de higiene bucal
BR112015012960A2 (pt) gel oral para o alívio da dor de dente
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
BR112016014530A2 (pt) Composição para cuidado oral e uso de um copolímero de fosfato/acrilato, um agente para controle do tártaro e um veículo oralmente aceitável
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112013026564A2 (pt) uso de uma combinação
BR112018073410A2 (pt) combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/68 , A61K 31/05 , A61K 31/352 , A61P 25/04 , C07C 39/23 , C07D 311/80

Ipc: A61K 9/68 (2006.01), A61K 31/05 (2006.01), A61K 31

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2017, OBSERVADAS AS CONDICOES LEGAIS.